Oligonucleotide Analytical Development: Five Hidden Traps And How To Avoid Them

Navigating oligonucleotide analytical development requires addressing severe analytical traps that extend far beyond simple sequence verification and basic purity testing. Chemically modified nucleic acid therapies generate complex, closely related impurities—such as truncated sequences and modified backbones—that often hide beneath main chromatographic peaks. Overlooking these nuances risks inaccurate purity data, misleading stability profiles, and unforeseen regulatory setbacks. Achieving true analytical confidence demands orthogonal techniques, including high-resolution mass spectrometry and specialized chromatography, coupled with matrix-aware sample handling protocols designed around the complete biological sample journey. Proactively tackling structural characterization and matrix interference early prevents severe delays during late-stage development and transfer.

Explore key strategies to refine impurity profiling, optimize characterization workflows, and build resilient analytical platforms.